Panacea Global to Present at Marcum MicroCap Conference
Thu, 29 May 2014
TORONTO, ONTARIO, May 29, 2014 (Marketwired via COMTEX) — Panacea Global Inc. PANG -14.75% ( www.panaceaglobalinc.com ) (“Panacea Global” or “the Company”) announced today that it will present at Third Annual Marcum MicroCap Conference in NYC.
Location: Grand Hyatt New York (109 E 42nd Street, New York, NY 10017)
Date: Thursday, May 29, 2014
Time: 4:30PM (ET)
Panacea Global will present an overview Dr. Mahmood Moshiri, President and CEO of Panacea Global, commented, “I look forward to presenting at the Marcum Investor Conference and providing an update on Company’s cancer diagnostic test and commercialization strategies.”
About Panacea Global
Panacea Global is a biotechnology company focused on the development and commercialization of diagnostic products for the management of cancer. Panacea has developed an accurate, timely, cost effective and non-invasive early cancer detection test to increase the quality of life of cancer patients and ultimately saving lives. Panacea’s test is based on the detection of the human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a novel biomarker expressed in malignant cancer cells in patients’ blood samples. Panacea Global has the exclusive worldwide (excluding the USA) rights to HAAH-based cancer tests. Panacea Global Inc.’s shares are publicly traded on the OTCBB under the ticker symbol PANG in the US. More information about Panacea Global is available at www.panaceaglobalinc.com.
Safe Harbor Statement
Certain information contained in this document may include forward-looking information. Without limiting the foregoing, the information and any forward-looking information may include statements regarding projects, costs, objectives and future returns of the Company or hypotheses underlying these items. In this document, words such as may, would, could, will, likely, believe, expect, anticipate, intend, plan, estimate and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or the Company management’s good-faith beliefs with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company’s control. The Company does not intend, nor does it undertake, any obligation to update or revise any forward-looking information or statements contained in this document to reflect subsequent information, events or circumstances or otherwise, except as required by applicable laws.